… experience depression and anxiety. Addressing these non-motor symptoms has not been the focus of Parkinson’s disease … that circuits in a specific brain region can be targeted by therapeutics to treat depression and anxiety … physiological measurements will provide insight into how the circuits are able to normalize network activity …

… remain unclear.  This study will use a pre-clinical model to test a potential mechanism by which neonatal brain … demonstrates that neonatal central inflammation, an event commonly occurring in human infants, enhances susceptibility …

… The ultimate aim in Parkinson’s disease research is to identify individuals at risk for developing Parkinson’s … of the disease with high accuracy. Prior evidence has shown that reliable prediction of the disease is not possible … biological signs of Parkinson’s, or biomarkers, lies in the comparatively rare occurrence of Parkinson’s in the general …

… In PD, lower GCase activity impacts cells’ ability to eliminate clumping of the protein alpha-synuclein, which … Gaucher patient-derived cells, we identified small molecule compounds to improve lysosomal function and increase active … advancement for patients. In addition, understanding how our compounds increase GCase activity and improve …

… hosted our annual gala “A Funny Thing Happened on the Way to Cure Parkinson’s” in New York. It was an amazing night of comedy and music. Denis Leary hosted the event and kicked it … crowd in hysterics. Lyrics included "Everyone is wondering how long I'm going to last. I'm Michael J. Fox, I'm kicking …

… from over 170 institutions gathered in New York City on October 19 to hear about novel advances in Parkinson’s disease … In opening remarks, MJFF Chief Program Officer Sohini Chowdhury recalled 2006, the first year of the conference, … for disease-modification was thin and longitudinal datasets comprising biological and clinical data from patients were …